PARTICIPANT CRITERIA

We are looking for participants who:

• Are at least 18 years of age
• Have a diagnosis/prominent symptoms of OCD
• Are regularly taking medication for OCD

We reluctantly cannot accept any participants who:

• Have any brain lesions or other clinically significant abnormalities
• Are pregnant
• Have any non-MRI safe implants
• Have a history of epilepsy or seizures

If you are interested in learning more about TMS, or have any questions or concerns about our study, please contact us below.

CONTACT US

Nick Bassano
Research Coordinator
tmsocdstudy@stanford.edu
WHAT IS TMS?

Background
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for treatment-resistant depression.

About the TMS Technology
Our study utilizes the Magventure Magpro System. More information can be found at: www.magventure.com

We are using an accelerated stimulation protocol which is not FDA-approved but has been deemed as non-significant risk by the FDA.

Procedure
During your TMS treatments, you will be awake and sitting in a chair. A magnetic device is placed over your head (pictured left). This device transmits magnetic waves to brain regions linked to OCD by research.

Potential Side Effects/Risks
The stimulation is generally painless. However, common side effects may include discomfort at the stimulation site, headache, and/or fatigue. The potential risk of TMS is seizure, but this is quite rare with an incidence rate of one in every 100,000 cases (1:100,000).

STUDY BACKGROUND
TMS has shown to be an effective form of treatment in individuals with treatment-resistant depression.

By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction.

Standard FDA-approved protocols involve a 3-minute stimulation session 5 days a week for a total of 6 weeks.

We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for up to 10 days.

TARGET BRAIN REGIONS
This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC and R-OFC. Both brain regions have been linked to OCD by research.

Dorsal Medial Prefrontal Cortex (DMPFC)  Right Orbitofrontal Cortex (R-OFC)

Superior View  Medial View
Patients that don't respond to their study region will have the option to receive stimulation at the other region.